Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

Prostate Cancer Prostatic Dis. 2025 Jun;28(2):503-505. doi: 10.1038/s41391-024-00811-5. Epub 2024 Feb 22.

Abstract

Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.

Publication types

  • Multicenter Study

MeSH terms

  • Abiraterone Acetate* / administration & dosage
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Follow-Up Studies
  • Gonadotropin-Releasing Hormone* / agonists
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / mortality
  • Prostatic Neoplasms* / pathology
  • Treatment Outcome

Substances

  • Abiraterone Acetate
  • Gonadotropin-Releasing Hormone
  • Prostate-Specific Antigen